Metropolitan Life Insurance Company (MetLife)’s Foghorn Therapeutics FHTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,295	Closed	-$6.47K	–	2362
2023 Q3	$6.47K	Hold	1,295	–	–	﹤0.01%	2370
2023 Q2	$9.12K	Buy	+1,295	New	+$9.05K	﹤0.01%	2340
2023 Q1	–	Sell	-1,439	Closed	-$9.18K	–	2363
2022 Q4	$9.18K	Sell	1,439 -181	-11%	-$1.36K	﹤0.01%	2304
2022 Q3	$13.9K	Hold	1,620	–	–	﹤0.01%	2188
2022 Q2	$22K	Hold	1,620	–	–	﹤0.01%	2007
2022 Q1	$24.7K	Sell	1,620 -4,949	-75%	-$67.9K	﹤0.01%	1994
2021 Q4	$150K	Hold	6,569	–	–	﹤0.01%	2220
2021 Q3	$91.5K	Buy	+6,569	New	+$72.7K	﹤0.01%	2569

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s FHTX Position: Q4 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Foghorn Therapeutics (FHTX) in Q4 2023, closing a stake of 1,295 shares — an estimated $6.47K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in FHTX in Q3 2021 and held it in 8 quarters. The position peaked at $150K in Q4 2021. 59 funds tracked by Wall St. Rank hold FHTX as of Q4 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Foghorn Therapeutics position as of Q4 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,295 Foghorn Therapeutics shares in Q4 2023, an estimated $6.47K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Foghorn Therapeutics in Q3 2021 and held it in 8 quarters.
Metropolitan Life Insurance Company (MetLife)'s Foghorn Therapeutics position peaked at $150K in Q4 2021.
59 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.